TRI-based people and companies are among the 100 leading innovators listed in The Australian, celebrating the ambition and commitment of the nation’s newest entrepreneurs. Among them are: TRI-based Dr Arutha Kulasinghe from The University of Queensland #FrazerInstUQ, listed along with colleagues Professor John Fraser and Associate Professor Kirsty Short (pictured). They are working on advanced mapping technology to help doctors understand how each cancer patient’s disease is progressing and responding to treatments. David Hoey, president and CEO of TRI alumni Vaxxas, aiming to commercialise novel technology that will dramatically enhance the performance of existing and next-generation vaccines by targeting the abundance of immune cells directly below the skin’s surface. Scott Kirkland and Stuart Crozier, CEO and Chief Scientific Officer from TRI-based EMVision Medical Devices - which has developed a backpack-sized brain scanner with the ability to detect a stroke in about five minutes, prompting accelerated diagnosis and treatment. https://lnkd.in/gzt-A9is
Translational Research Institute Australia
Research
Woolloongabba, QLD 13,802 followers
An Australian-first bench-to-bedside medical research institute, translating medical discoveries into improved health.
About us
The TRI is a medical research institute based in Brisbane, Australia, interfacing directly with hospital clinicians, government and industry to improve the success of scientific discoveries translated into real treatments and diagnostics for improved health outcomes.
- Website
-
http://www.tri.edu.au
External link for Translational Research Institute Australia
- Industry
- Research
- Company size
- 501-1,000 employees
- Headquarters
- Woolloongabba, QLD
- Type
- Nonprofit
- Founded
- 2012
- Specialties
- medical research, teaching, cervical cancer, breast cancer, prostate cancer, melanoma, liver and kidney disease, osteoporosis, obesity, diabetes, immunology, and immunotherapy
Locations
-
Primary
37 Kent Street
Woolloongabba, QLD 4102, AU
Employees at Translational Research Institute Australia
Updates
-
Congratulations to the TRI-based team from the QUT (Queensland University of Technology) Centre for Microbiome Research (CMR), finalists in the 2024 Research Australia Awards for the Frontiers Award, sponsored by the The Australian National University. The awards are Research Australia's recognition of the outstanding efforts and achievements of individuals and teams who drive and support the opportunities that health and medical innovation bring to each and every one of our lives. Under the leadership of Professor Gene Tyson, the CMR team develops molecular approaches and bioinformatics tools to answer important questions about the role of microbial communities in human and environmental health. They will join other finalists, their nominators, parliamentarians, key sector influencers and fellow Research Australia members, for celebrations and the announcement of winners on November 14.
-
It was our pleasure to host delegates from The Bioprocessing Network Conference to showcase TRI, our translational manufacturing facility under construction, and our neighbours Thermo Fisher Scientific. A wonderful opportunity for us to detail our biomedical infrastructure that services start-ups in the medtech/biotech sector.
A huge thank you to Kym Baker and Glenda Colburn for organizing such an insightful and exciting tour last Friday at the Translational Research Institute Australia(TRI) and Thermo Fisher Scientific Australia! 🙌 The feedback from attendees has been fantastic—everyone truly enjoyed the opportunity to get a behind-the-scenes look at both facilities. We also want to extend our gratitude to the teams who made the day run so smoothly. Your expertise and hospitality were greatly appreciated! Special thanks as well to Kym and Glenda for sponsoring the lovely morning tea, which provided the perfect start to a productive day.
-
It's Breast Cancer Awareness Month. It's almost time for scientists, clinicians and advocates to gather at TRI tomorrow for the Public Breast Cancer Research Forum, with a workshop focused on creating international connections and presentations under the themes of empowerment and collaboration. Among the TRI-based presenters are A/Prof Fernando Guimaraes, Prof Kum Kum Khanna from Mater Research, A/Prof Fiona Simpson and Prof Erik Thompson. The forum is supported by TRI, the National Breast Cancer Foundation, PA Research Foundation, Health Translation Queensland, QUT (Queensland University of Technology) and The University of Queensland #FrazerInstUQ Read more: https://lnkd.in/gXm5sced
-
Welcome to TRI, Matt Zeller, and thank you for engaging in conversations about Queensland's biomedical ecosystem and role in pharmaceutical development. TRI is proud of our role in supporting early-phase biotech companies, including by building our translational manufacturing facility that enables them to build, test and develop their products. The facility is under construction and due to open in 2026. Life Sciences Queensland Ltd (LSQ) Novartis, Australia & New Zealand Ryan Parlett Belinda McEniery Michelle Gregory
LSQ was delighted to give a big #Queensland welcome to Novartis, Australia & New Zealand Country President Matt Zeller at the Translational Research Institute Australia today. Matt met with LSQ’s Acting CEO Dr Ryan Parlett to talk about the Queensland #biomedical ecosystem, Novartis’ expanding footprint in Queensland and LSQ’s strategic review. It was a timely conversation to have on how we can all work together to continue to build the sector and ultimately deliver innovative medicines to Queenslanders. 🤝 Matt joined the Swiss pharma giant as Country President late last year, and we are delighted to now welcome Novartis as an #LSQMember. 👏 👏 👏 #pharmaceuticals #InnovativeMedicines #radiopharmaceuticals #ClinicalTrials | Belinda McEniery | Michelle Gregory
-
It was wonderful to have a front row seat at the launch of the Queensland Drug Discovery Alliance launch, held at TRI with experts from across the sector. QDDA aims to make interactions with different infrastructures more seamless, supporting translational projects and fostering innovation. It brings together Compounds Australia (Griffith University), the Queensland Emory Drug Discovery Initiative (UniQuest) and the Centre for Integrated Preclinical Drug Development (The University of Queensland). Therapeutic Innovation Australia Griffith University Institute for Biomedicine and Glycomics Life Sciences Queensland Ltd (LSQ) Department of Environment, Science and Innovation MTPConnect Queensland Government Brandon Capital Health Translation Queensland Queensland Health Stuart Newman Trent Munro Mark Jacobs Ross McKinnon Professor Sally-Ann Poulsen Brian Dymock Maree Smith AC Andrew Bowskill
-
It's Breast Cancer Awareness Month. TRI-based Associate Professor Fiona Simpson leads a research team aiming to better predict which patients will benefit from current cancer treatments - and improve treatment options for those who don’t. Her research team from The University of Queensland #FrazerInstUQ is studying cellular processes, the immune system’s ability to target tumours, and the most effective ways for medicines to work in unison with the immune system. The team uses lab-grown cancer cells and live tissues from cancer patients, testing medicines that have already been approved and determining the right concentration to be effective – including one used as an anti-nausea treatment, but used at a specific high concentration. The anti-nausea medication has been shown in preclinical research models to boost the body’s immune cells to recognise and kill the cancer cells.. Team members are now investigating its uses beyond cancer and looking at delivery of medicines more broadly. Associate Professor Simpson will be among the scientists, clinicians and advocates at TRI on Friday 18 October for the Public Breast Cancer Research Forum: https://lnkd.in/gXm5sced
-
Rarely has a visitor to TRI generated such a buzz as Nobel Laureate Professor Peter Doherty AC FRS FMedSci. We enjoyed hearing about his career, from vet to scientist; his incredible successes as an immunologist; and his insight in politics, the pharmaceutical industry, and the future of research. TRI used the opportunity to showcase the translational research conducted here, our facilities and our collaborations; as well as introduce the next generation of research leaders. Thank you, Professor Doherty, for an incredible day of insights, recollections and laughter. The University of Queensland UQ Institute for Molecular Bioscience #FrazerInstUQ QUT (Queensland University of Technology) Mater Research Queensland Health Metro South Health
Nobel Laureate Professor Peter Doherty Visits TRI, Sharing Career Insights and Inspiring Future Leaders
-
Congratulations to all the TRI-based students recognised for their excellent research and presentation skills during the TRI Student Symposium. Organised by the OneTRI Student Committee, the symposium included a poster session and a suite of oral presentations. There were also early-career researchers facilitating discussions and career sessions with guest speakers from industry, academia, operations, clinical research and core facilities. Those recognised included: - Best PhD talk: Rizky Nurdiansyah, QUT (Queensland University of Technology) - Best Masters/Honours talk: Jenna Theron, The University of Queensland #FrazerInstUQ - Runner-up, student talk: Lilibeth Cárdenas, QUT - People's choice, talk: Wendy Kao, UQ - Best PhD poster: Bhadra Kerala Varma, UQ - Best Masters/ Honours poster: Danielle Gavanescu, UQ - Runner-up, poster: Chenping Du, Mater Research - People's choice, poster: Giuseppina Guida, QUT
-
TRI-based Dr Arutha Kulasinghe from The University of Queensland #FrazerInstUQ and Queensland Spatial Biology Centre (QSBC) aims to create an incredibly detailed map of the cells that make up head and neck cancer. “This means examining the tumours at a microscopic level to understand every cell and how they interact with their neighbours. We can think of this process as zooming into the tumour with a really high-powered lens to uncover the secrets hidden in every corner," Dr Kulasinghe says. The aim is to gain a deeper understanding of how head and neck cancer tumours respond to treatment. The research has received the support of a Ramaciotti Health Investment Grant. Read more: https://lnkd.in/gNHKp6Td Perpetual Limited